Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122706943 | 12270694 | 3 | F | 20160218 | 20160718 | 20160415 | 20160720 | EXP | DE-TEVA-639857GER | TEVA | 7.00 | DEC | M | Y | 93.00000 | KG | 20160720 | MD | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 122706943 | 12270694 | 1 | SS | Lonquex | LIPEGFILGRASTIM | 1 | LAST DOSE PRIOR TO AE: 10-FEB-2016 | ASKU | 0 | ||||||||||
| 122706943 | 12270694 | 2 | SS | DOXORUBICIN | DOXORUBICIN | 1 | Intravenous (not otherwise specified) | LAST DOSE PRIOR TO AE: 09-FEB-2016 | ASKU | 0 | 80 | MG | Q3W | ||||||
| 122706943 | 12270694 | 3 | PS | VINCRISTINE | VINCRISTINE | 1 | Intravenous (not otherwise specified) | LAST DOSE PRIOR TO AE: 09-FEB-2016 | ASKU | 75493 | 1 | MG | Q3W | ||||||
| 122706943 | 12270694 | 4 | SS | Cyclophosphamid | CYCLOPHOSPHAMIDE | 1 | Intravenous (not otherwise specified) | LAST DOSE PRIOR TO AE: 09-FEB-2016 | ASKU | 0 | 1200 | MG | Q3W | ||||||
| 122706943 | 12270694 | 5 | C | Rituximab | RITUXIMAB | 1 | Intravenous (not otherwise specified) | 0 | 750 | MG | Q3W | ||||||||
| 122706943 | 12270694 | 6 | C | RAMIPRIL. | RAMIPRIL | 1 | Oral | 5 MILLIGRAM DAILY; | 0 | 5 | MG | QD | |||||||
| 122706943 | 12270694 | 7 | C | ATENOLOL. | ATENOLOL | 1 | Oral | 25 MILLIGRAM DAILY; | 0 | 25 | MG | QD | |||||||
| 122706943 | 12270694 | 8 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | Oral | 12.5 MILLIGRAM DAILY; | 0 | 12.5 | MG | QD | |||||||
| 122706943 | 12270694 | 9 | C | Pantoprazol | PANTOPRAZOLE SODIUM | 1 | Oral | 40 MILLIGRAM DAILY; | 0 | 40 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 122706943 | 12270694 | 1 | Neutropenia |
| 122706943 | 12270694 | 2 | Non-Hodgkin's lymphoma |
| 122706943 | 12270694 | 3 | Non-Hodgkin's lymphoma |
| 122706943 | 12270694 | 4 | Non-Hodgkin's lymphoma |
| 122706943 | 12270694 | 5 | Non-Hodgkin's lymphoma |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 122706943 | 12270694 | DE |
| 122706943 | 12270694 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 122706943 | 12270694 | Death | |
| 122706943 | 12270694 | Infection |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 122706943 | 12270694 | 1 | 20160210 | 20160210 | 0 | |
| 122706943 | 12270694 | 2 | 20160209 | 20160209 | 0 | |
| 122706943 | 12270694 | 3 | 20160209 | 20160209 | 0 | |
| 122706943 | 12270694 | 4 | 20160209 | 20160209 | 0 | |
| 122706943 | 12270694 | 5 | 20160208 | 2016 | 0 | |
| 122706943 | 12270694 | 6 | 2016 | 0 | ||
| 122706943 | 12270694 | 7 | 2016 | 0 | ||
| 122706943 | 12270694 | 8 | 2016 | 0 | ||
| 122706943 | 12270694 | 9 | 2016 | 0 |